cobitolimod

DRUG2 trials

Sponsors

InDex Pharmaceuticals

Conditions

Colitis, UlcerativeUlcerative Colitis

Phase 2

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis

CompletedNCT03178669

InDex PharmaceuticalsUlcerative Colitis

Start: 2017-06-21End: 2019-08-30Updated: 2021-02-01

Phase 3

The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients

CompletedNCT01493960

InDex PharmaceuticalsColitis, Ulcerative

Start: 2011-12-31End: 2014-03-31Updated: 2023-01-10

Related Papers

Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.

2020-10-0535 citations

OP004 The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis

Journal of Crohn s and Colitis2018-01-16